Argos Therapeutics Publishes Positive Immune Response, Safety and Manufacturing Data for its Arcelis(TM) HIV Program in Clinical Immunology

Argos Therapeutics announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company's Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient's unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART). The study demonstrated that AGS-004 is capable of producing a proliferative T cell response to HIV-1 antigens in patients,...

Want to see the full article?

• Purchase this article for only $3.00